» Articles » PMID: 35876288

Matrix Proteoglycans in Tumor Inflammation and Immunity

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer immunoediting progresses through elimination, equilibrium, and escape. Each of these phases is characterized by breaching, remodeling, and rebuilding tissue planes and structural barriers that engage extracellular matrix (ECM) components, in particular matrix proteoglycans. Some of the signals emanating from matrix proteoglycan remodeling are readily co-opted by the growing tumor to sustain an environment of tumor-promoting and immune-suppressive inflammation. Yet other matrix-derived cues can be viewed as part of a homeostatic response by the host, aiming to eliminate the tumor and restore tissue integrity. These latter signals may be harnessed for therapeutic purposes to tip the polarity of the tumor immune milieu toward anticancer immunity. In this review, we attempt to showcase the importance and complexity of matrix proteoglycan signaling in both cancer-restraining and cancer-promoting inflammation. We propose that the era of matrix diagnostics and therapeutics for cancer is fast approaching the clinic.

Citing Articles

The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review.

Douglah S, Khalil R, Kanaan R, Almeqbaali M, Abdelmonem N, Abdelmessih M PeerJ. 2024; 12:e18486.

PMID: 39583112 PMC: 11586047. DOI: 10.7717/peerj.18486.


High-throughput glycosaminoglycan extraction and UHPLC-MS/MS quantification in human biofluids.

Volpi N, Galeotti F, Gatto F Nat Protoc. 2024; .

PMID: 39543382 DOI: 10.1038/s41596-024-01078-9.


Glycosylation in the tumor immune response: the bitter side of sweetness.

Cao Y, Yi W, Zhu Q Acta Biochim Biophys Sin (Shanghai). 2024; 56(8):1184-1198.

PMID: 38946426 PMC: 11399423. DOI: 10.3724/abbs.2024107.


Bone marrow inflammation in haematological malignancies.

de Jong M, Chen L, Raaijmakers M, Cupedo T Nat Rev Immunol. 2024; 24(8):543-558.

PMID: 38491073 DOI: 10.1038/s41577-024-01003-x.


Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity.

Papadas A, Huang Y, Cicala A, Dou Y, Fields M, Gibbons A Biochem Soc Trans. 2023; 51(6):2017-2028.

PMID: 38031753 PMC: 10754280. DOI: 10.1042/BST20221083.


References
1.
Prieto-Fernandez E, Egia-Mendikute L, Bosch A, Garcia Del Rio A, Jimenez-Lasheras B, Antonana-Vildosola A . Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment. Front Immunol. 2020; 11:586977. PMC: 7561406. DOI: 10.3389/fimmu.2020.586977. View

2.
Merline R, Schaefer R, Schaefer L . The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal. 2009; 3(3-4):323-35. PMC: 2778586. DOI: 10.1007/s12079-009-0066-2. View

3.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

4.
Aoyama E, Yoshihara R, Tai A, Yamamoto I, Gohda E . PKC- and PI3K-dependent but ERK-independent proliferation of murine splenic B cells stimulated by chondroitin sulfate B. Immunol Lett. 2005; 99(1):80-4. DOI: 10.1016/j.imlet.2005.01.005. View

5.
Binette F, CRAVENS J, Kahoussi B, Haudenschild D, GOETINCK P . Link protein is ubiquitously expressed in non-cartilaginous tissues where it enhances and stabilizes the interaction of proteoglycans with hyaluronic acid. J Biol Chem. 1994; 269(29):19116-22. View